Ovid Therapeutics (OVID)
(Delayed Data from NSDQ)
$0.50 USD
0.00 (-0.04%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $0.49 -0.01 (-1.27%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OVID 0.50 0.00(-0.04%)
Will OVID be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OVID based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OVID
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Fortrea Holdings Inc. (FTRE) Q1 Earnings and Revenues Beat Estimates
OVID: What are Zacks experts saying now?
Zacks Private Portfolio Services
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for OVID
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference | OVID Stock News
Ovid Therapeutics management to meet with B. Riley
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Thursday's Intraday Session
Upcoming B. Riley Meeting Features Key Insights for OVID Investors | OVID Stock News